Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. - Wikidata - awgldk - TriplyDB

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

http://www.wikidata.org/entity/Q36544977

about

Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa.PharmGKB summary: Efavirenz pathway, pharmacokinetics Clinically relevant drug-drug interactions between antiretrovirals and antifungals Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults Neuropsychiatric side effects of efavirenz therapy.Advances in pharmacogenomics of antiretrovirals: an update.Pharmacologic consideration for the use of antiretroviral agents in the elderly.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Warfarin-antiretroviral interactions.Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.Antigen negative gastrointestinal histoplasmosis in an AIDS patient Drug interactions with antiretrovirals and warfarin.Therapeutic drug monitoring in highly active antiretroviral therapy.Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.Opinion: Paracoccidioidomycosis and HIV Immune Recovery Inflammatory Syndrome.Depression associated with antiretroviral drug therapy in HIV: case report and overview.Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in -negative HIV-infected Malawian adults stabilized on antiretroviral therapy

P2860

Q28477719-D9AEADF2-E345-4629-86D3-49DE94D2FC17 Q34137766-74CE67F2-18CB-43E0-90EC-D844A9BD6ADF Q34851665-83198D37-A754-4807-B8C5-58C8FE039BA6 Q35018246-351CA617-DFB4-4B4E-BCAA-9A207EFEF3B6 Q35501523-3E532258-77C9-4FCE-BD01-EB1EE5AB5872 Q35602042-7710CDF1-1AA6-4508-ACF9-94FD48DFEA71 Q35706069-22563BD1-733E-486F-A71D-93BCFCE1A85F Q35892563-EB5A9DBF-4338-4624-ADBA-6F20792727FE Q36300127-3924E32C-5BC0-4954-94E6-D6CF30EC384E Q36762436-F8C2EB90-A72E-400F-8338-8FE951554BF5 Q36966025-F870D49C-FFC7-4BD3-A17E-EE0CF447E364 Q37277510-D5610665-C778-436C-83AC-E2300B17F8B1 Q37378110-A693BC14-8FAB-4F1F-85A9-5CB5ADD855C1 Q37386503-6DA8DE62-8D79-411C-AF5F-B526621FC3B4 Q37481442-C180AD72-6D45-402E-B4A4-ADD7582BC31E Q37619670-1845D862-7B00-4524-A3FD-9E4B32802E00 Q37679935-EB3113FC-CD94-493C-B162-DE20639EB381 Q37720765-C0631588-6A73-4C02-9983-9697B3F480B0 Q38868951-182091F8-E197-4BE5-A80B-9E247E7C29C5 Q46032916-5DEB23EA-260F-4F84-96A0-43033FEA1417 Q47437785-311BE5A2-985C-4075-AF9E-EE65AAEDC424 Q48642405-23F8FADB-2802-4810-B6BF-BD622984358E Q56339581-15107141-E9F8-40D3-BA0A-809D88DB1A51

P2860

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

http://www.wikidata.org/entity/Q36544977

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

@ast

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

@en

type

label

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

@ast

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

@en

prefLabel

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

@ast

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

@en

P1433

Q36544977-45169F03-2D41-41F1-8DC3-629433FD8887

P1476

Q36544977-463966CD-C267-4248-93DC-ADBE698E04FE

P2093

Q36544977-338B09AA-CD81-477F-AA20-E653A787EBCA

Q36544977-552B6B6D-D796-480E-AAFB-86E4C73FDBF3

Q36544977-69441D2A-3DAC-4D1D-AC97-F60A75217A83

Q36544977-88D96AB9-C987-4FFA-A961-B55994754AB2

Q36544977-B72F71DD-544E-4634-B0C4-7D356C88B922

Q36544977-C8E6403F-12CC-42BC-B69D-33754BED0E3E

Q36544977-E3C337FA-90BF-49F6-8323-DA9A3F292CF4

Q36544977-E5F9446A-3545-4AD4-8EE0-D337150DD460

P2860

Q36544977-007C0A0B-7A7E-48BE-90CA-8A4B156DE824

Q36544977-0116F076-4971-4652-BA56-1DAD7B288D59

Q36544977-02911409-D875-4238-9316-00702DFEC83E

Q36544977-03223F99-0B4D-441F-8CBD-45511CA715DF

Q36544977-0551D675-A885-4BD2-A15B-67DF0AC4FAE4

Q36544977-0B8FD964-CE30-4C1F-93CF-EB1240F8743A

Q36544977-10FB65F5-7425-4B0D-A4D7-C85D1B65FC80

Q36544977-13157B53-A8E5-4FEB-BD91-182479A6BD2C

Q36544977-1D7FD034-1ACF-4F1C-975F-F47C59B8DA11

Q36544977-1D892465-A0EE-47B1-892A-710EDD63E4ED

P304

Q36544977-97B09DBF-8837-46F2-B8AA-620B08D916CB

P31

Q36544977-C92BBD06-76F5-406F-B7F9-256D45D3E906

P356

Q36544977-5BEA33C9-BEFD-4D78-ABDE-261186422C9C

P407

Q36544977-03806539-25F8-4838-844F-AB3901FBB505

P433

Q36544977-7BFE3A2C-61D0-4AD1-BFC1-701AB87F782C

P478

Q36544977-826C621B-9773-4EA0-BF50-DB22CF5BADB6

P577

Q36544977-46674788-7EEC-4C41-BAA5-3584FCEAD2B9

P698

Q36544977-96A245B8-23BD-408D-9D85-E3EACE26A39C

P356

17425255.1.3.473

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

@en

P2093

Alan Forrest

http://www.w3.org/2001/XMLSchema#string

Gene D Morse

http://www.w3.org/2001/XMLSchema#string

Judianne C Slish

http://www.w3.org/2001/XMLSchema#string

Linda M Catanzaro

http://www.w3.org/2001/XMLSchema#string

Olanrewaju O Okusanya

http://www.w3.org/2001/XMLSchema#string

Patrick F Smith

http://www.w3.org/2001/XMLSchema#string

Qing Ma

http://www.w3.org/2001/XMLSchema#string

Robert Dicenzo

http://www.w3.org/2001/XMLSchema#string

P2860

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.

Significant interactions with new antiretrovirals and psychotropic drugs.

Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.

A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals

The effect of garlic supplements on the pharmacokinetics of saquinavir.

Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease.

P304

473-485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.1.3.473

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16863456

http://www.w3.org/2001/XMLSchema#string